Previous close | 2.1000 |
Open | 2.1500 |
Bid | 1.9500 |
Ask | 2.2000 |
Strike | 5.00 |
Expiry date | 2024-06-21 |
Day's range | 1.8000 - 2.2000 |
Contract range | N/A |
Volume | |
Open interest | 2.43k |
Key Insights Humacyte to hold its Annual General Meeting on 11th of June Salary of US$603.8k is part of CEO Laura...
On May 31, 2024, Heather Prichard, Chief Operating Officer of Humacyte Inc (NASDAQ:HUMA), sold 191,511 shares of the company, according to the SEC Filing.
DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, in New York, NY on Thursday, June 6, 2024. Management will also be available for one-on-one meetings. Event: Jefferies Global Healt